Cullinan Therapeutics (CGEM) Cash & Equivalents (2020 - 2026)

Cullinan Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $351.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 15.83% year-over-year to $351.9 million; the TTM figure through Mar 2026 stood at $351.9 million (up 15.83% YoY), while the FY2025 annual figure was $88.3 million, up 6.42% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $351.9 million, up from $88.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $611.0 million in Q2 2022, with the low at $72.8 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $242.7 million (2022), against an average of $264.9 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 394.06% in 2022, then slumped 76.61% in 2024.
• Cullinan Therapeutics' Cash & Equivalents stood at $156.2 million in 2022, then sank by 36.96% to $98.4 million in 2023, then dropped by 15.67% to $83.0 million in 2024, then gained by 6.42% to $88.3 million in 2025, then jumped by 298.38% to $351.9 million in 2026.
• Business Quant data shows CGEM's Cash & Equivalents at $351.9 million in Q1 2026, $88.3 million in Q4 2025, and $332.6 million in Q3 2025.